Identification and characterization of cytochrome P4502D6*56B (CYP2D6*56B), a novel allele associated with the poor metabolizer phenotype.

被引：0
|
作者：
Gaedigk, A. [1 ]
Eklund, J. D. [1 ]
Pearce, R. E. [1 ]
Leeder, J. S. [1 ]
Alander, S. W. [1 ]
Bradford, L. D. [1 ]
Kennedy, M. J. [1 ]
机构：
[1] Univ Louisville, Childrens Mercy Hosp, Morehouse Sch Med, Kansas City, MO USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2007年 / 81卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：S85 / S85
页数：1
相关论文
共 50 条
  • [21] Change from the CYP2D6 extensive metabolizer to the poor metabolizer phenotype during treatment with bupropion
    Güzey, C
    Nordström, Å
    Spigset, O
    THERAPEUTIC DRUG MONITORING, 2002, 24 (03) : 436 - 437
  • [22] A rare insertion of T-226 in exon 1 of CYP2D6 causes a frameshift and is associated with the poor metabolizer phenotype: CYP2D6*15
    Sachse, C
    Brockmoller, J
    Bauer, S
    Reum, T
    Roots, I
    PHARMACOGENETICS, 1996, 6 (03): : 269 - 272
  • [23] The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation
    de Leon, J
    Susce, MT
    Pan, RM
    Fairchild, M
    Koch, WH
    Wedlund, PJ
    JOURNAL OF CLINICAL PSYCHIATRY, 2005, 66 (01) : 15 - 27
  • [24] Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype:: a role for the CYP2D6*35 allele in ultrarapid metabolism?
    Lovlie, R
    Daly, AK
    Matre, GE
    Molven, A
    Steen, VM
    PHARMACOGENETICS, 2001, 11 (01): : 45 - 55
  • [25] Association between cytochrome P4502D6 (CYP2D6) genotype, antipsychotic exposure, and abnormal involuntary movement scale (AIMS) score
    Ellingrod, VL
    Schultz, SK
    Arndt, S
    PSYCHIATRIC GENETICS, 2000, 10 (01) : 9 - 11
  • [26] Epitope mapping of cytochrome P4502D6 (CYP2D6) autoantigen in patients with chronic hepatitis C under α-interferon treatment.
    Dalekos, G
    Wedemeyer, H
    Obermayer-Straub, P
    Kayser, A
    Barut, A
    Frank, H
    Manns, M
    HEPATOLOGY, 1998, 28 (04) : 508A - 508A
  • [27] Association between cytochrome P4502D6 (CYP2D6) genotype, neuroleptic exposure, and abnormal involuntary movement scale (AIMS) score
    Ellingrod, VL
    Schultz, SK
    Arndt, S
    Perry, PJ
    Andreasen, NC
    Holman, TL
    Fleming, F
    SCHIZOPHRENIA RESEARCH, 1999, 36 (1-3) : 90 - 90
  • [28] DETECTION OF THE POOR METABOLIZER-ASSOCIATED CYP2D6(D) GENE DELETION ALLELE BY LONG-PCR TECHNOLOGY
    STEEN, VM
    ANDREASSEN, OA
    DALY, AK
    TEFRE, T
    BORRESEN, AL
    IDLE, JR
    GULBRANDSEN, AK
    PHARMACOGENETICS, 1995, 5 (04): : 215 - 223
  • [29] MAJOR INFLUENCE OF THE CYP2D6*41 ALLELE ON CYP2D6 METABOLIZER PHENOTYPE - A STUDY ON 1,021 VENLAFAXINE-TREATED PATIENTS
    Haslemo, T.
    Eliasson, E.
    Jukic, M.
    Ingelman-Sundberg, M.
    Molden, E.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2018, 123 : 8 - 8
  • [30] IDENTIFICATION OF A NEW VARIANT CYP2D6 ALLELE LACKING THE CODON ENCODING LYS-281 - POSSIBLE ASSOCIATION WITH THE POOR METABOLIZER PHENOTYPE
    TYNDALE, R
    AOYAMA, T
    BROLY, F
    MATSUNAGA, T
    INABA, T
    KALOW, W
    GELBOIN, HV
    MEYER, UA
    GONZALEZ, FJ
    PHARMACOGENETICS, 1991, 1 (01): : 26 - 32
12345